[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363168-105":59,"doc-detail-363168-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","early-versus-late-onset-gastroesophageal-cancer-real-world-outcomes-from-a-13-year-central-european-cohort-study","Early-versus late-onset gastroesophageal cancer - real-world outcomes from a 13-year central European cohort study","","Gastroesophageal cancer varies by age, with early-onset (EO) presenting distinct pathological and clinical features compared with late-onset (LO) disease. This retrospective Central European cohort study examines differences and real-world treatment outcomes in patients treated between 2010 and 2022 at a comprehensive cancer center. Patients were grouped as EO (\u003C50 years) or LO (≥50 years), comparing clinicopathological traits across the full cohort and survival and treatment patterns among adenocarcinoma patients.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/early-versus-late-onset-gastroesophageal-cancer-real-world-outcomes-from-a-13-year-central-european-cohort-study/363168/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/early-versus-late-onset-gastroesophageal-cancer-real-world-outcomes-from-a-13-year-central-european-cohort-study/363168.png","ImageObject",300,407,{"name":92,"@type":93},"Cart","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How were early-onset (EO) and late-onset (LO) gastroesophageal cancer groups defined in the study?","Question",{"text":112,"@type":113},"EO was defined as patients younger than 50 years, while LO included patients aged 50 years or older.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What real-world treatment and survival outcomes were compared between EO and LO patients?",{"text":117,"@type":113},"The study compared clinicopathological characteristics across the cohort, and assessed treatment patterns and survival outcomes among adenocarcinoma patients.",{"name":119,"@type":110,"acceptedAnswer":120},"Did early-onset gastroesophageal cancer lead to improved survival compared with late-onset disease?",{"text":121,"@type":113},"No significant survival benefit was observed; median overall survival was 9.1 months for EO and 9.6 months for LO.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},363168,1790197911,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},18829141979164,"https://eur-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Gastric Cancer (2026) 29:494–505  \n[https://doi.org/10.1007/s10120-026-01724-z](https://doi.org/10.1007/s10120-026-01724-z)  \nORIGINAL ARTICLE  \nEarly-versus late-onset gastroesophageal cancer: real-world outcomes from a 13-year central European cohort study  \nTomas Sokop1,2 · Iveta Selingerova3,4,5 · Vaclav Jedlicka6,7 · Lumir Kunovsky8,9,10 · Igor Kiss1,2 ·  \nRadka Lordick Obermannova1,2,3,5  \nReceived: 26 August 2025 / Accepted: 4 February 2026 / Published online: 27 March 2026 © The Author(s) 2026  \nAbstract  \nBackground Gastroesophageal cancer presents variably across different age groups, with early-onset (EO) cases showing distinct pathological and clinical characteristics compared to late-onset (LO) disease. This study aims to delineate these differences and assess treatment outcomes in a Central European population.  \nMethods Data from patients diagnosed with gastroesophageal carcinoma and treated between 2010 and 2022, at a highvolume comprehensive cancer center representing approximately 5% of all national gastroesophageal cancer cases in the Czech Republic, were retrospectively analyzed. Patients were categorized into EO (\u003C 50 years) and LO (≥ 50 years) groups. Clinicopathological characteristics were compared in the entire cohort, while treatment patterns and survival outcomes were evaluated in patients with adenocarcinoma.  \nResults A total of 1,377 patients were included, with 161 (11.7%) classified as EO. EO patients are more frequently present with ECOG performance status 0 (42%), lower BMI, current smoking (44%), gastric cancer primaries (63%), and aggressive tumor characteristics such as poorly cohesive adenocarcinoma subtype (45%) and metastatic disease (55%). Hereditary cancer syndrome was confirmed in 4.3% of EO cases. Among adenocarcinoma patients, triplet chemotherapy was more frequently used in the EO group (29% vs. 11%, p\u003C 0.001) in the first-line setting. However, no significant survival benefit was observed in inoperable or metastatic disease (median overall survival 9.1 vs. 9.6 months in EO and LO, respectively, p = 0.913) .  \nConclusions EO gastroesophageal cancer in the Central European population is associated with distinct clinicopathological characteristics, with no significant impact on survival.  \nMiniabstract This study identifies distinct clinicopathological characteristics in early-onset gastroesophageal cancer in Central Europe, characterized by more aggressive attributes but without significant survival differences compared to late-onset cases.  \nKeywords Gastric cancer · Esophageal cancer · Europe · Adult · Treatment outcome  \nAbbreviations  \ndMMR Mismatch repair deficient EBV Epstein-Barr virus  \nECOG Eastern Cooperative Oncology Group  \nGAPPS Gastric adenocarcinoma and proximal polyposisof the stomach  \nGEJ Gastroesophageal junction  \nHER-2 Human epidermal growth factor receptor 2  \nTomas Sokop and Iveta Selingerova have contributed equally to this work.  \nExtended author information available on the last page of the article  \nIQR  \nLAP  \nNOS  \nNS  \nInterquartile range Lymphadenopathy Not otherwise specified  \nNot specified, PD-L1,programmed-death ligand 1  \nIntroduction  \nGastric cancer ranks fifth among solid tumors affecting adolescents and young adults (AYAs), with a global burden estimated at 1,570,000 disability-adjusted life years (DALYs)  \n[1] . Recent data from the SEER program indicate a rising incidence of early-onset (EO) gastric cancer, defined using a 60-year age threshold, along with an increased incidence of esophageal adenocarcinoma, as a less common subtype [2] . Contrastingly, the Czech Republic’s more socio-demographically homogeneous population exhibits a different trend; data from the National Cancer Registry indicate a consistent decline in both incidence and mortality rates for EO gastric and esophageal cancers over recent decades [3] . Numerous lifestyle-related risk factors have been identified as contributors to the development of these malignancies, each p","cbCaiuvERjpDszaM","https://ap.wps.com/l/cbCaiuvERjpDszaM","pdf",1733480,12,"English","# Abstract\n# Methods\n## Study design and patients\n# Results\n# Conclusions\n# Keywords\n# Abbreviations\n# Introduction","[{\"question\":\"How were early-onset (EO) and late-onset (LO) gastroesophageal cancer groups defined in the study?\",\"answer\":\"EO was defined as patients younger than 50 years, while LO included patients aged 50 years or older.\"},{\"question\":\"What real-world treatment and survival outcomes were compared between EO and LO patients?\",\"answer\":\"The study compared clinicopathological characteristics across the cohort, and assessed treatment patterns and survival outcomes among adenocarcinoma patients.\"},{\"question\":\"Did early-onset gastroesophageal cancer lead to improved survival compared with late-onset disease?\",\"answer\":\"No significant survival benefit was observed; median overall survival was 9.1 months for EO and 9.6 months for LO.\"}]","Early-versus late-onset gastroesophageal cancer - real-world outcomes from a 13-year central European cohort study | PDF",1790150252,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/270c512a408a0ac7381ed86d2a1579de.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cca2e6c55932122634e8877ea0a9404b.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3f8befdd642b8b9a7f4068c3c91ea2d6.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/23333f3c317ef90e8ae9dbc2241b722c.webp",980,1301]